Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
07:00am, Wednesday, 19'th Feb 2025
2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webc
Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm
05:59pm, Monday, 17'th Feb 2025
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amicus Therapeutics, Inc. (NASDAQ: FOLD) brea
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
10:30am, Monday, 17'th Feb 2025
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics
10:20am, Monday, 17'th Feb 2025
Besides Wall Street's top -and-bottom-line estimates for Amicus Therapeutics (FOLD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared d
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Wednesday, 12'th Feb 2025
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
07:00am, Monday, 10'th Feb 2025
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 202
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
07:00am, Monday, 03'rd Feb 2025
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at th
NCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement Cases
03:38pm, Thursday, 23'rd Jan 2025
Cornelius Campbell Burgess v. Administrative Law Judge Jennifer Whang, Federal Deposit Insurance Corp., Acting Chairman Martin J. Gruenberg, Director Michael J. Hsu, Director Rohit Chopra Cornelius Ca
NCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act Enjoined
01:46pm, Monday, 13'th Jan 2025
Merrick Garland, Attorney General of the United States, et al. v. Texas Top Cop Shop, Inc., et al. Merrick Garland, Attorney General of the United States, et al. v. Texas Top Cop Shop, Inc., et al.
3 Oversold Biotech Names
12:56pm, Monday, 13'th Jan 2025
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook
12:37pm, Monday, 13'th Jan 2025
FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025.
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
04:00pm, Sunday, 12'th Jan 2025
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year 1
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07:00am, Thursday, 02'nd Jan 2025
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43rd Annual J.P.
Amicus Therapeutics: Cheap Heading Into 2025
01:33pm, Friday, 27'th Dec 2024
Amicus Therapeutics, Inc.'s shares are down 15% recently despite a profitable 3Q24 and raised FY24 outlook, potentially due to market overreaction. The company markets Galafold for Fabry disease and P
NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote It
03:43pm, Monday, 23'rd Dec 2024
Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food an
